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Objective: The objective of this selective EBM review is to determine whether or not ketamine 
is effective in reducing depressive symptoms in adults with treatment-resistant major depressive 
disorder.  
 
Study Design: A systematic review of 3 randomized, double-blind placebo controlled trials 
performed in or after the year 2016.  
 
Data Sources: All 3 studies published in peer-reviewed journals found on PubMed and 
Cochrane Collection.  
 
Outcome Measures: The studies utilized quantitative scales, either the Montgomery-Asberg 
Depression Scale (MADRS) or Hamilton Depression Rating Scales (HAMD) for the POEM, 
depressive symptoms. 
 
Results: George et al. (Am J Geriatr Psychiatry. 2017;25(11):1199-1209. doi: 
10.1016/j.jagp.2017.06.007) did show significant reduction in depressive symptoms with 
0.2mg/kg ketamine SQ and the severity of the depressive episode downgraded compared to the 
placebo of midazolam at day 2 and induced remission in some individuals. Chen et al. (J Affect 
Disord. 2018;225:709-714. doi: 10.1016/j.jad.2017.09.008) additionally found a significant 
change in depressive symptoms from 0.2mg/kg ketamine infusion compared to the placebo.  
However, Su et al. (Neuropsychopharmacology. 2017;42(13):2482-2492. doi: 
10.1038/npp.2017.94) results of 0.2mg/kg ketamine displayed near equal reduction between the 
intervention and placebo of saline solution at day 2. 
 
Conclusion: This EBM shows that more studies need to be performed before one could 
recommend ketamine as an intervention for treatment resistant MDD. The reductions in the short 
term were significant and encourage the capability of ketamine as a bridge therapy or short term 
episodic treatment.  
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Introduction 
 Major depressive disorder (MDD) is a debilitating episodic mood disorder that affects the 
day to day functions of those afflicted.  It has a multitude of symptoms that vary in their 
presentation and effect on normal daily activities, ranging from mild symptoms like change in 
appetite and loss of energy to the most damaging, suicidal ideation. The condition affects men 
and women, young and old, and across socioeconomic status. It is treated with combination of 
psychotherapy and pharmacologic agents, starting with selective serotonin reuptake inhibitors 
(SSRIs). However, the prevalence of multi-drug resistant MDD has spurred research for novel 
pharmacologic agents.  
Major depressive disorder (MDD) affects 3.7-6.7% of the world population, with 
increased incidence when considering just depressive symptoms in the general public.1,2 The 
diagnosis of MDD requires the presence of 5 out of 9 symptoms of insomnia, depressed mood, 
guilt, anhedonia, change in appetite, change in cognition, loss of energy, feeling of 
worthlessness, and suicidal ideation during a 2-week period. After diagnosis patients are treated 
in primary care, psychiatry and psychology practices, emergency rooms, and many other 
specialties with a pharmacologic agent, usually an SSRI. Best practice includes a referral for 
psychotherapy. With the prevalence of MDD and variety of specialties in which physician 
assistants (PAs) see these patients, it is common for PAs to be asked to initiate medication or 
continue their prescriptions.  
Patients with MDD, and especially treatment resistant MDD, require multiple visits for 
their care and in turn MDD has a high treatment cost. In 2010, the economic burden in the US 
for treatment of MDD was estimated at a total of $210.5 billion.2 The average total cost, 
including medical visits and the pharmacy payments was $19,626 per treatment-resistant MDD 
episode. This is per episode, rather than annual cost, meaning that a patient can have an episode 
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last longer than 365 days or can have recurrent episodes per year in treatment-resistant MDD.3 
Patients with treatment resistant MDD have an increased duration of a depressive episode, more 
severe symptoms, increased likelihood of suicidal ideations, increased pharmacy costs, and 
possible hospitalization compared to a newly diagnosed or easily treated MDD depressive 
episode.  Unfortunately, the amount of healthcare visits for MDD are difficult to estimate due to 
the high incidence of comorbidities that could be the primary diagnosis for healthcare utilization 
while MDD is also being managed. However, patients suffering from MDD with increased 
relapse and remission, which falls under treatment-resistant MDD, have a yearly average of 27 
outpatient visits, 1 emergency department visit, and 1-day inpatient visit.3 The increased 
outpatient visits and potential inpatient management lead to the aforementioned economic 
burden of treatment-resistant MDD care.2 
MDD is pervasive and elusive in treating in part because the exact pathophysiology of the 
disease is unknown. While it has been studied extensively, the exact mechanism of the condition 
is not fully understood. First, there is the biochemical hypothesis, in which neurotransmitter 
synthesis, breakdown and receptor sensitivity are altered. These neurotransmitters traditionally 
targeted by medication are dopamine, norepinephrine, and most often, serotonin. Second is the 
neuroendocrine hypothesis, in which endocrine axis such as thyroid hormone and cortisol affect 
neuroprocessing. This hypothesis is supported by the incidence of MDD and depressive 
symptoms in individuals with endocrine pathologies including Addison’s disease and 
hypothyroidism.  Thirdly is the hypothesis that early life stressors affect the development of the 
brain and its function. This is currently being researched with results displaying a correlation 
between stressful events in childhood directly relating to mental health diseases later in life.  
These hypotheses establish the different forms of therapies, psychiatric or pharmacologic, 
for MDD.  Starting with the gold standard of treatment for MDD is a combination of 
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psychotherapy performed by a therapist and pharmacologic anti-depressant agents. The first line 
treatment include SSRIs such as sertraline (Zoloft), paroxetine (Paxil), citalopram (Celexa), and 
escitalopram (Lexapro). If those are unsuccessful or the side effects are undesirable, patients can 
try serotonin norepinephrine reuptake inhibitors like venlafaxine (Effexor), desvenlafaxine 
(Pristiq), and duloxetine (Cymbalta) that target norepinephrine in addition to serotonin, in case 
the patient’s current depressive episodes are caused by a lack of norepinephrine rather than 
serotonin alone. If those do not work, there are other tricyclic antidepressants which block the 
enzymes transporting neurotransmitters and increasing their concentrations in the brain, like 
amitriptyline (Elavil) or MAO-inhibitors that block the degradation of neurotransmitters such as 
selegiline (Zelapar), isocarboxazid (Marplan), phenelzine (Nardil). Furthermore, other 
medications can augment the effectiveness of the aforementioned medications including 
antipsychotics such as aripiprazole (Abilify). Ultimately, if pharmacologic therapy fails, 
electroconvulsive therapy can be used to stimulate and reset the brain, aiming to recalibrate the 
neurotransmitter deficiency. 
Despite all the drugs available to address MDD, multi-drug resistant MDD leaves patients 
suffering with little pharmacologic support. Treatment resistant MDD decreases the patient’s 
quality of life and the current treatments for MDD take weeks to be effective, leaving the patient 
to struggle. New therapies need to be effective and rapid acting. Ketamine is useful to address 
this time disparity as it is fast acting. Ketamine is also useful, as it targets a different 
neurotransmitter than other antidepressants, glutamate. Ketamine acts on the N-methyl-D-
aspartate receptor as an antagonist, blocking the efficacy of the excitatory neurotransmitter 
glutamate in the CNS. The studies evaluated for this review studied the effectiveness this 
glutamine receptor antagonism has on depressive symptoms in treatment resistant MDD. While 
new delivery methods are being explored, like the use of nasal spray, the studies evaluated for 
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the purposes of this paper had ketamine administered SQ or IV and therefore has been given as 
repeated clinician administered doses in the management of MDD.  
Objective  
The objective of this selective EBM review is to determine whether or not ketamine is effective 
in reducing depressive symptoms in adults with treatment-resistant major depressive disorder. 
Methods  
 The studies that were selected had specific populations, interventions, comparisons, 
outcomes measured and types of study in order to adequately compare the findings for the 
objective.  The population studied were adults of both genders with treatment-resistant MDD.  
The intervention was 0.2 mg/kg of ketamine infused or injected, compared to placebo: either 
saline or 0.01 mg/kg midazolam (Versed). The outcomes measured for these interventions were 
depressive symptoms rated using quantitative scales. And all of these studies that were selected 
were double-blind random controlled trials.  
 All of the studies were personally researched by the author on PubMed and Cochrane 
Collection. They were selected with the inclusion and exclusion criteria of relevance in order to 
have studies of recent use: published during or after the year 2016 and the treatment studied be 
applicable to the desired population of adults with treatment-resistant MDD. Thus, the inclusion 
criteria were studies in or after 2016 and random controlled trials. Conversely, the exclusion 
criteria were studies in or before 2015 and systematic reviews.  Furthermore, the results had to be 
in patient-oriented evidence that mattered rather than disease-oriented evidence. The key words 
in the searches were “ketamine” & “depression”.  All of the studies selected were in English and 
published in peer-reviewed journals. The statistics reported or used were the number needed to 
treat, relative benefit index, absolute benefit index, mean change. More information of studies 
can be found in Table 1.  
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Table 1. Demographics & Characteristics of Included Studies 
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Outcomes 
The outcomes measured by the selected studies were depressive symptoms such as 
depressed mood, low energy, anhedonia, insomnia, feelings of guilt, and suicide using 
quantitative scales: the Montgomery-Asberg Depression Scale (MADRS) & Hamilton 
Depression Rating Scales (HAMD). Both of these scales are clinician performed with numeric 
scaling counted by the number of depressive symptoms reported and observed. These scales are 
useful in the diagnosis of MDD, categorizing its severity, and measuring progress of therapy in 
downgrading the patient’s MDD episode or inducing remission. The MADRS score is calculated 
from a 10-item assessment.  For severity classification, the MADRS score is out of 60 and a 
score of 9-17 is mild depression, 18-34 is moderate, and >35 is severe. The HAMD score is a 21-
item assessment of depressive symptoms with a maximum score of 52. For the scale, 8-13 is 
classified as mild depression, 14-18 as moderate depression, 19-22 as severe depression, and ³23 
for very severe depression. For the purposes of this paper, only the quantitative score and 
severity were extrapolated with these scales. 
 
Results  
 The papers examined had multiple variables and data about the performance of ketamine 
for MDD.  However, for the purposes of this systematic review, we examined the measurement 
of symptoms at day 2 in assessing the significance of ketamine on depressive symptoms and the 
data included about ketamine inducing remission.  This time frame for analysis will add weight 
to ketamine’s utility as an effective, fast acting anti-depressant.  
George et al. was a double blind RCT that presented outcomes as dichotomous data for 
those achieving remission (MADRS score <10) and continuous data involving subcutaneous 
injections of ketamine at 0.02 mg/kg compared to the control midazolam.4 This study used the 
MADRS score to study the efficacy of the injection. Total, the study had 16 participants at its 
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start but lost 2 participants due to physical illness and family illness, leaving 14 to receive the 
dosing.4  The study did perform an intention-to-treat for those lost in its final results but did not 
calculate as a “worst-case” analysis.4 The process for the study was to be assessed with a 
MADRS rater blind to treatment at multiple intervals: pre-treatment, 4 hours post, and day 2, 4, 
7.4  The results for this study reported a p-value of <0.01.4 For those receiving 0.02 mg/kg 
ketamine, the absolute benefit index was 0.045 and the NNT was 23 for remission.4 This is a 
considerably high number when evaluating the utility of ketamine for MDD.  Looking at 
continuous data instead of remission, this study’s evaluation of ketamine shows a significant 
reduction in depressive symptoms at day 2. In Table 2, the mean percentage change in MADRS 
score was 49.7% on day 2 compared to the control of 25.3%.4 This greater reduction at day 2 is 
enough to reduce the category of MDD from a baseline of “severe depression” to “mild 
depression”.  
Table 2. Mean Changes in MADRS Scores in George et al.4 
 Baseline MADRS Day 2 MADRS (Mean Change %) 
0.2mg/kg ketamine SQ 34.8 17.5 (49.7%) 
Midazolam 34.8 26 (25.3%)  
 
Chen et al. was a double blind RCT that presented outcomes as continuous data involving 
the IV infusion of 0.2 mg/kg of ketamine compared to the control of normal saline infusion.  
This study utilized the HAMD score to study the efficacy of this treatment. Total, the study had 
24 participants start and complete the treatment.5  Individuals were assessed by a rater for 
HAMD scores 40, 80, 120, 240 min after the infusion and on day 2.5  This study was precise 
with a p-value of <0.001.5  For those receiving the 0.02 mg/kg ketamine infusion the day 2 
change from baseline was 25.3%, while the control mean change was 11.9%.5  This change 
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would down grade individuals from “very severe depression” to “severe depression” in just one 
day.  
Su et al. performed a double blind RCT as well that presented outcomes as continuous 
data involving the IV infusion of 0.2 mg/kg of ketamine compared to a control of normal saline 
infusion.6 Similar to Chen et al., it used the HAMD score to study the efficacy of this treatment 
and the comparison of these two studies is shown in Table 3. Su et al. had a similar amount of 
individuals that had 0.2 mg/kg ketamine, with 23 individuals receiving the dose and completing 
the study.7 The individuals were assessed for their response to the infusion at multiple intervals: 
40, 80, 120, 240 min and then day 2, 3, 4, 5, 6, 7, and 12.7  For those receiving 0.02 mg/kg 
ketamine, at day 2 the mean change was 23.3%, while the control group mean change was 
22.8%. These both barely downgraded the severity from “very severe depression” to “severe 
depression”. These results were precise with a p-value of 0.05.6  
Table 3: Mean Changes in HAMD Score  
 Baseline HAMD Day 2 HAMD (Mean change %) 
Chen et al.5 Saline (control) 24.63 21.8 (11.9%) 
Chen et al.5 0.2mg/kg ketamine IV 27.13 20.27 (25.3%) 
Su et al.6 Saline (control) 28 21.63 (22.8%) 
Su et al.6 0.2mg/kg ketamine IV 28 21.47 (23.3%) 
 
Discussion  
 First, from assessing the data the studies show an immediate short-term effect of 
ketamine on depressive symptoms, the question at hand is the significance of that short term 
effect.  Downgrading the severity of depression in these individuals is significant, however there 
were few instances of remission in these studies and at the dose of 0.2mg/kg.  Only George et al. 
had patients achieve remission at that dose of ketamine.4 More studies have to be considered at 
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this dose of ketamine and at higher doses to establish if ketamine can be used as a substitute for 
other anti-depressants, not just augmentation. Furthermore, one has to consider the other factors 
into receiving care. Ketamine as a SQ injection can be handled by the patient once the patient has 
been adequately trained but with IV a patient has to go to the doctor’s office with capability of 
setting up an IV in order to receive the medication. There are multiple barriers in getting patients 
to the office, having the physical capability, the money to ride the bus or drive, the time to have 
off work in order to receive the medication, and the question of insurance coverage for the 
treatment.   
There were no serious adverse effects reported in the studies performed with a smaller 
dose of 0.2mg/kg but ketamine does have the adverse effects like dissociation, psychotomimetic 
effects, and the potential for abuse due to its intoxicating, euphoric sensation at larger doses, 
particularly the doses used for anesthesia. This is why the studies examined in this paper 
excluded those with psychotic illnesses and history of substance abuse. Ketamine administration 
also does not exist independently pharmacologically and can interact with other medications an 
individual is receiving.  It is not recommended for use with other CNS depressants like alcohol, 
benzodiazepines, or opioids.8 Additionally, any individual receiving thyroid medication for 
hypothyroidism is not recommended to use ketamine due to the increased sympathetic effects.8  
 When looking at these studies for areas of improvement and confounding information, 
they had small sample sizes and treated individuals who were classified with more severe 
depressive episodes.  This data collected shows a transient significant reduction in depressive 
symptoms but this cannot be extrapolated and generalized to any adult with MDD, nor can these 
studies make the claim that ketamine at 0.2mg/kg would be useful for treatment-resistant 
depression with a depressive severity of mild or low moderate on the HAMD or MADRS scales. 
Further studies have to include individuals with treatment resistant depression with lower 
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baseline HAMD and MADRS scores.  Also, when examining the mean change from baseline 
between Chen et al. and Su et al., one can appreciate the larger change in Chen.5  However, this 
study allowed individuals to continue their current anti-depressant treatment during the course of 
ketamine treatments.  This confounds the data; we cannot confidently say the decrease from 
mean score is from a combination effect of standard anti-depressant therapy with ketamine added 
on or is from the ketamine itself.  
Conclusion  
 In answering the question of is 0.2mg/kg ketamine effective in reducing depressive 
symptoms in treatment resistant MDD compared to placebo or a control medication like 
midazolam, the answer cannot be identified with the studies analyzed.  The evidence from the 
studies are conflicting and the results are unclear. George et al. had the largest change in 
depressive symptoms and severity of depression on day 2 compared to the other groups, however 
it was the smallest sample size of all of the studies.4 Additionally, Chen and Su et al. were 
comparable in size and same treatment delivery, however the results were different.5,6  Chen et 
al. showed a more significant reduction in depressive symptoms, but it did have the confounding 
effect of patients continuing their normal anti-depressant medication regimen.5  Future studies 
should not only consider an increase in the amount of participants and length of treatment, but 
also need to evaluate exclusive ketamine use for treatment resistant MDD and should include 
individuals in a depressive episode with lower HAMD and MADRS scores to ensure ketamine is 
useful for milder, treatment resistant depression before routine use is recommended to the 
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